Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rodger Israel

Internal Medicine Raleigh, NC Medical Doctor

NPI 1073508149 CMS profile 229619

3237 Blue Ridge Rd, Raleigh, NC 27612

Open in the dashboard

General payments

$3,038

205 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$75,000 paid to institutions, not to them · program year 2023

Through program year 2025, Rodger Israel of Raleigh, NC is reported in the CMS Open Payments database as having received $3,038 across 205 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $75,000 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 84th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $422 23
2024 General $496 27
2023 General $272 16
2022 General $333 22
2021 General $188 13
2020 General $189 14
2019 General $1,139 90

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rodger Israel
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Rodger Israel were reported at $422. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Rodger Israel Internal Medicine median Middle half National median
2019 $1,139 $159 $48–$570 $163
2020 $189 $119 $33–$402 $114
2021 $188 $135 $37–$521 $132
2022 $333 $141 $42–$496 $149
2023 $272 $149 $45–$519 $160
2024 $496 $154 $47–$537 $164
2025 $422 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $727 47 payments
  2. Lilly USA, LLC $360 26 payments
  3. Amgen Inc. $309 22 payments
  4. Pfizer Inc. $190 17 payments
  5. Janssen Pharmaceuticals, Inc $184 17 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $164 10 payments
  7. Abbott Laboratories $149 7 payments
  8. Astellas Pharma US Inc $144 9 payments
  9. Daiichi Sankyo Inc. $131 8 payments
  10. Amarin Pharma Inc. $76 5 payments
  11. Other $605 37 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,030 204 payments
  2. Education $8 1 payment
Products named General payments · program years 2019–2025
  1. Ozempic $469 31 payments
  2. RYBELSUS $279 17 payments
  3. EVENITY $175 11 payments
  4. MOUNJARO $174 11 payments
  5. XARELTO $174 16 payments
  6. Wegovy $172 10 payments
  7. INVOKANA $157 15 payments
  8. JARDIANCE Diabetes $130 11 payments
  9. JARDIANCE Diabetes $125 8 payments
  10. ELIQUIS $112 11 payments
  11. Other $2,213 154 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 132 drugs

Part D claims

7,733

Median for Internal Medicine: 777

Drug cost

$582,563

Median for Internal Medicine: $73,373

Branded share of claims

18.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 86 $110,425
Jardiance Empagliflozin Brand 48 $63,108
Ozempic Semaglutide Brand 49 $50,987
Xarelto Rivaroxaban Brand 50 $39,279
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 32 $37,443
Trulicity Dulaglutide Brand 23 $35,366
Januvia Sitagliptin Phosphate Brand 27 $32,873
Arexvy Rsvpref3 Antigen/As01e/Pf Brand 76 $24,042
Breo Ellipta Fluticasone/Vilanterol Brand 26 $17,139
Farxiga Dapagliflozin Propanediol Brand 14 $14,664

The 10 drugs with the highest cost, of 132 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 117 billing codes

Paid by Medicare

$143,503

Of which drugs: $16,278

Medicare patients

302

Average age 78

Services billed

6,530

131 women, 171 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 70%
Arthritis 39%
Atrial fibrillation 23%
Ischemic heart disease 22%
Cancer 22%
Diabetes 21%
Heart failure 16%
Chronic kidney disease 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 52 53 $4,035
Sarscv2 vac 30mcg trs-suc im 91320 Office 20 20 $2,903
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 13 1,300 $110

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 13 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $73
$73 — —
TZIELD
  • SANOFI-AVENTIS U.S. LLC $54
$54 — —
RYBELSUS
  • Novo Nordisk Inc $36
$36 — —
Ozempic
  • Novo Nordisk Inc $36
$36 49 —
MOUNJARO
  • Lilly USA, LLC $31
$31 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 13 in the dashboard with a free account

Records

205 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record